Safety and efficacy evaluations for nanomaterials often include in vitro and in vivo studies to understand their toxicology, biodistribution, and pharmacokinetics. Regulatory bodies may require extensive preclinical and clinical data before approving nanotechnology-based products. These evaluations are crucial to ensure that nanomaterials do not pose unforeseen risks to humans or the environment.
